ASCO 2025 insights: EVERSANA experts on AI, biomarkers, and the future of oncology

Oncology

Tim Lewis, Vanitha Sankaran, Sarah Henry, Jordan Schell - with pharmaphorum

At ASCO 2025, pharmaphorum web editor Nicole Raleigh sat down to discuss key highlights from the Congress with EVERSANA experts.

With Tim Lewis, EVP, Strategic Development, Oncology and Precision Medicine at EVERSANA INTOUCH; Vanitha Sankaran, SVP, Medical Strategy, EVERSANA INTOUCH; Sarah Henry, Director, Medical Strategy, EVERSANA INTOUCH; and Jordan Schell, Principal at EVERSANA MANAGEMENT CONSULTING – the conversation covers biomarkers and ctDNA, AI and certainty, hype and underappreciation, and remaining issues of access, and more.

Watch the discussion below, and be sure to catch up with the wider pharmaphorum coverage of ASCO 2025 here.